Development pipeline
Development code; Target/Indication(s) |
Target exploration | Optimization (sequence, type of nucleic acid) |
Efficacy, toxicity, metabolism studies, etc. (Preliminary nonclinical studies) |
Non-clinical studies | Phase I | Phase II |
---|---|---|---|---|---|---|
BNC-1021/TRK-250; TGF-β1/IPF |
![]() ![]() ![]() ![]() |
![]() ![]() ![]() ![]() |
![]() ![]() ![]() ![]() |
![]() ![]() ![]() ![]() |
![]() ![]() ![]() ![]() |
- |
BNC-1601; (pro)renin receptor/AMD, Uveitis, Diabetic retinopathy |
![]() ![]() ![]() ![]() |
![]() ![]() ![]() ![]() |
![]() ![]() |
- | - | - |
BNC-1701; Virus/HBV |
![]() ![]() ![]() ![]() |
![]() ![]() ![]() ![]() |
![]() ![]() |
- | - | - |
BNC-1322; SARS-CoV-2/COVID-19 |
![]() ![]() ![]() ![]() |
![]() ![]() ![]() ![]() |
![]() ![]() |
- | - | - |
BNC-1602; miR29b/liver fibrosis |
![]() ![]() ![]() ![]() |
![]() ![]() ![]() ![]() |
![]() |
- | - | - |
Not disclosed | ![]() ![]() ![]() ![]() |
![]() |
- | - | - | - |